Beyond Biotech - the podcast from Labiotech
TCR-NK: A novel cell therapy transforming cancer treatment
Are TCR-NK treatments the next big thing in cell therapies for cancer patients?
As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norwegian biotech is taking a slightly different track.
This week, we sit down with Namir Hassan, CEO of Zelluna, a company with a mission to eliminate solid cancers by pioneering the development of T cell receptor guided natural killer, or TCR-NK, cell therapies.
01:45 Introducing Namir Hassan
03:37 Working at Immunocore
04:40 Lessons learned
06:56 Joining Zelluna as CSO
08:44 Becoming Zelluna CEO
10:20 Taking a biotech company public
12:54 TCR-T and TCR-NK therapies
15:30 Targets for TCR-NK therapies
16:38 Comparing TCR-NK to alternatives
20:16 Early success
21:58 An off-the-shelf-solution for cancer patients
24:16 Manufacturing and scaling
25:13 Partnering with top pharma, accelerating innovation
27:05 Milestones ahead for Zelluna
28:52 The landscape of TCR therapies in oncology
31:38 A final word
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Remember Everything You Learn from Podcasts
